{
  "id": "589a246878275d0c4a000030",
  "type": "yesno",
  "question": "Is vortioxetine effective for treatment of depression?",
  "ideal_answer": "Yes. Vortioxetine is the most recently approved medication for the treatment of major depressive disorder.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26346592",
    "http://www.ncbi.nlm.nih.gov/pubmed/25249164",
    "http://www.ncbi.nlm.nih.gov/pubmed/25851751",
    "http://www.ncbi.nlm.nih.gov/pubmed/26525043",
    "http://www.ncbi.nlm.nih.gov/pubmed/21154150",
    "http://www.ncbi.nlm.nih.gov/pubmed/26641142",
    "http://www.ncbi.nlm.nih.gov/pubmed/24787143",
    "http://www.ncbi.nlm.nih.gov/pubmed/25087600",
    "http://www.ncbi.nlm.nih.gov/pubmed/24284262",
    "http://www.ncbi.nlm.nih.gov/pubmed/26464458",
    "http://www.ncbi.nlm.nih.gov/pubmed/26035186",
    "http://www.ncbi.nlm.nih.gov/pubmed/27067232",
    "http://www.ncbi.nlm.nih.gov/pubmed/24424707",
    "http://www.ncbi.nlm.nih.gov/pubmed/24165478",
    "http://www.ncbi.nlm.nih.gov/pubmed/22171087",
    "http://www.ncbi.nlm.nih.gov/pubmed/22495621",
    "http://www.ncbi.nlm.nih.gov/pubmed/25650503",
    "http://www.ncbi.nlm.nih.gov/pubmed/22209361",
    "http://www.ncbi.nlm.nih.gov/pubmed/23252878",
    "http://www.ncbi.nlm.nih.gov/pubmed/26035185",
    "http://www.ncbi.nlm.nih.gov/pubmed/24570588",
    "http://www.ncbi.nlm.nih.gov/pubmed/25893002",
    "http://www.ncbi.nlm.nih.gov/pubmed/23757185",
    "http://www.ncbi.nlm.nih.gov/pubmed/24311349",
    "http://www.ncbi.nlm.nih.gov/pubmed/22963932",
    "http://www.ncbi.nlm.nih.gov/pubmed/25562777",
    "http://www.ncbi.nlm.nih.gov/pubmed/24257717",
    "http://www.ncbi.nlm.nih.gov/pubmed/23531115",
    "http://www.ncbi.nlm.nih.gov/pubmed/26546771",
    "http://www.ncbi.nlm.nih.gov/pubmed/26358483",
    "http://www.ncbi.nlm.nih.gov/pubmed/22978748",
    "http://www.ncbi.nlm.nih.gov/pubmed/26679430",
    "http://www.ncbi.nlm.nih.gov/pubmed/25418918",
    "http://www.ncbi.nlm.nih.gov/pubmed/24524096",
    "http://www.ncbi.nlm.nih.gov/pubmed/21767441",
    "http://www.ncbi.nlm.nih.gov/pubmed/27139079",
    "http://www.ncbi.nlm.nih.gov/pubmed/26316764",
    "http://www.ncbi.nlm.nih.gov/pubmed/24871704",
    "http://www.ncbi.nlm.nih.gov/pubmed/26020712",
    "http://www.ncbi.nlm.nih.gov/pubmed/24676550",
    "http://www.ncbi.nlm.nih.gov/pubmed/21486038",
    "http://www.ncbi.nlm.nih.gov/pubmed/25907797",
    "http://www.ncbi.nlm.nih.gov/pubmed/22572889",
    "http://www.ncbi.nlm.nih.gov/pubmed/25260373",
    "http://www.ncbi.nlm.nih.gov/pubmed/24169027",
    "http://www.ncbi.nlm.nih.gov/pubmed/23903233",
    "http://www.ncbi.nlm.nih.gov/pubmed/25350320",
    "http://www.ncbi.nlm.nih.gov/pubmed/24684240",
    "http://www.ncbi.nlm.nih.gov/pubmed/22901346",
    "http://www.ncbi.nlm.nih.gov/pubmed/25874839"
  ],
  "snippets": [
    {
      "text": "Vortioxetine is the most recently approved medication for the treatment of major depressive disorder (MDD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Vortioxetine: a new antidepressant to treat depressive episodes].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7\u00a0receptors and the serotonin transporter (5-HTT). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In short-term studies (8\u00a0weeks), vortioxetine is more efficacious than placebo in decreasing depressive symptoms as measured by the MADRS total score, response rate (vortioxetine: 53.2% vs placebo: 35.2%) and remission rate (vortioxetine: 29.2% vs placebo: 19.3%). In a long-term study (52\u00a0weeks), vortioxetine is also superior to placebo in preventing relapses and recurrences. Moreover, in second line treatment, after failure of a first line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrin reuptake inhibitor (SNRI), vortioxetine is superior to agomelatine in improving depressive symptoms and achieving response and remission. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-HT1A, 5-HT3 and 5-HT7 which may account for their specific effects on certain symptoms of depression (e.g. cognition and anxiety) as well as a characteristic side-effect profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464458",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26641142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine: a New Treatment for Major Depressive Disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTRODUCTION: Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "EXPERT OPINION: Results of placebo-controlled trials suggest efficacy and an overall safety profile comparable to existing first-line antidepressants. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24570588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine was significantly more effective than was placebo, with a standardized mean difference (SMD) of\u00a0-0.118 (95% CIs,\u00a0-0.203 to\u00a0-0.033, P\u00a0=\u00a00.007).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25851751",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine for the treatment of depression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Vortioxetine for the treatment of major depression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Vortioxetine (Lu-AA-21004; 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide) is a novel orally active molecule that is being investigated by Lundbeck and Takeda for the treatment of major depression and generalized anxiety disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine (Lu AA21004) is a multi-modal antidepressant in clinical development for the treatment of major depressive disorder (MDD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963932",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10\u2009mg in acute treatment of adults with generalized anxiety disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Secondary endpoints included response and remission rates, anxiety symptoms(Hamilton Anxiety Rating Scale), Clinical Global Impression, overall functioning (Sheehan Disability Scale), health-related quality of life(EuroQol 5 Dimensions), productivity (work limitation questionnaire) and family functioning (Depression and Family Functioning Scale).RESULTS: Primary endpoint noninferiority was established and vortioxetine (n = 252) was superior to agomelatine (n = 241) by 2.2 MADRS points (p<0.01).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition of the serotonin transporter.To evaluate the efficacy of vortioxetine 10 and 20 mg once daily in outpatients with major depressive disorder.This 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study was conducted from July 2010 to January 2012 among adults with a primary diagnosis of recurrent major depressive disorder (DSM-IV-TR).Eligible subjects were randomized in 1:1:1 ratio to 1 of 3 treatment arms: vortioxetine 10 mg, vortioxetine 20 mg, or placebo once daily for 8 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine (Lu AA21004) is a new antidepressant that combines a number of neurotransmitter reuptake and receptor effects that have been thought to predict efficacy as a treatment for depressive and anxiety disorders.This review summarizes the pharmacology and neurobiology of vortioxetine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24684240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the study of elderly patients, vortioxetine 5 mg (n = 136) improved 12-item Health Status Questionnaire scores significantly more than placebo (n = 148) for the domains of health perception (10.4, P &lt; 0.0001, SES of 0.54), mental health (7.9, P &lt; 0.001, SES of 0.44), and energy (6.4, P &lt; 0.05, SES of 0.28) (FAS, mixed model for repeated measures).Vortioxetine yielded significant, meaningful HRQoL improvements in 6 MDD studies of 6 to 8 weeks duration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All references included were published between 1999 and 2014.All studies that included humans and were published in English, with data describing vortioxetine for the treatment of MDD, were reviewed.Vortioxetine is a novel multimodal antidepressant agent, which inhibits the 5-HT transporter protein, acts as a 5-HT3 antagonist, 5-HT1A receptor agonist, 5-HT7 receptor antagonist, and a partial agonist of the 5-HT1B receptor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine is an antidepressant with multimodal activity which has shown efficacy in major depressive disorder (MDD) patients in six of ten short-term, randomized, placebo-controlled trials (completed end 2012).We performed meta-regression analyses to indirectly compare vortioxetine to seven marketed antidepressants with different mechanisms of action",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25249164",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data were available from 51 human trials involving vortioxetine, and included a total of 7,666 healthy volunteers and patients with a diagnosis of major depressive disorder (MDD) or generalized anxiety disorder who were exposed to at least 1 dose of vortioxetine for a total of 2,743 patient-years.Vortioxetine was effective in treating MDD in the United States at a dose of 20 mg/d",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562777",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies.This double-blind, placebo-controlled study assessed the efficacy and tolerability of vortioxetine in subjects with a primary diagnosis of generalized anxiety disorder.Subjects (n\u2009=\u2009457) were randomized 1:1:1 to treatment with placebo or vortioxetine 2.5 or 10\u2009mg once daily",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was a significant difference for nausea between the two groups (OR=3.01, 95 % CI=2.22-4.09, Z=7.08, P=0.00001), but no significant differences were observed for the other four adverse effects.CONCLUSIONS: For the treatment of major depressive disorder, our results show that a dose of 5 mg/day vortioxetine was more effective, but more easily induced nausea, compared to placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24871704",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24871704",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24570588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The incidence of treatment-emergent adverse events was significantly higher in the duloxetine group than in the vortioxetine group.Duloxetine was more effective but less well-tolerated than vortioxetine in MDD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was no significant difference in discontinuation rates between vortioxetine and comparators owing to inefficacy (OR 0.983, 95% CI 0.585 to 1.650), whereas discontinuation owing to AEs was significantly less common in the vortioxetine than in the comparator group (OR 0.728, 95% CI 0.554 to 0.957).Studies examining the role of vortioxetine in the treatment of MDD are limited.Although our results suggest that vortioxetine may be an effective treatment option for MDD, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a l",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We performed a meta-analysis to increase the statistical power of these studies and enhance our current understanding of the role of vortioxetine in the treatment of MDD.We performed an extensive search of databases and the clinical trial registry.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies.OBJECTIVE: This double-blind, placebo-controlled study assessed the efficacy and tolerability of vortioxetine in subjects with a primary diagnosis of generalized anxiety disorder.METHODS: Subjects (n\u2009=\u2009457) were randomized 1:1:1 to treatment with placebo or vortioxetine 2.5 or 10\u2009mg once daily.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine significantly improved objective and subjective measures of cognitive function in adults with recurrent MDD and these effects were largely independent of its effect on improving depressive symptoms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24787143",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, a statistically significant number of patients with MDD who were on vortioxetine have achieved a greater than or equal to 50% reduction in depression symptoms from baseline.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although our results suggest that vortioxetine may be an effective treatment option for MDD, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of heterogeneous RCTs..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine is an effective agent for the treatment of MDD, but it does not have any clear advantages over other available treatment options..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine was significantly more effective than placebo for acute treatment of major depressive disorder (MDD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874839",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duloxetine was more effective but less well-tolerated than vortioxetine in MDD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine is an orally administered small molecule developed by Lundbeck A/S for the once-daily treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). Vortioxetine received its first global approval for MDD in the USA in September 2013 and regulatory approval for its use in this indication in the EU (where it has received a positive opinion) and Canada is awaited. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24311349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of vortioxetine leading to this first approval for MDD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24311349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine was efficacious and well tolerated in the treatment of patients with major depressive disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257717",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On the primary efficacy endpoint, both vortioxetine doses were statistically significantly superior to placebo, with a mean difference to placebo (n=158) of -5.5 (vortioxetine 15 mg, P<0.0001, n=149) and -7.1 MADRS points (vortioxetine 20 mg, P<0.0001, n=151).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257717",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The change in the severity of depressive and anxiety symptoms was maintained throughout the study as reflected by a 24-item Hamilton Depression Scale total score of 8.2 at week 52 (from 17.6 at open-label baseline) in the observed case data set.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24169027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine is a multi-modal antidepressant that functions as a human 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the serotonin transporter. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Approval for the treatment of MDD was based on a clinical development programme that included six positive 6-8 week studies, including one study in elderly people, and one positive maintenance study in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vortioxetine represents another option for the treatment of MDD. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The multimodal compounds vortioxetine and vilazodone are examples of this approach with diverse mechanisms, and their different clinical effects will provide valuable insights into serotonergic modulation of glutamate transmission for the potential treatment of depression and associated cognitive dysfunction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903233",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two new antidepressant drugs, vilazodone (marketed in the USA) and vortioxetine (in development) incorporate partial 5-HT1A-R agonist properties with SERT blockade.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Novel drugs in development include those that combine multiple simultaneous pharmacologic mechanisms in addition to SERT inhibition within the same molecule, such as vilazodone (combining 5HT1A partial agonism with SERT inhibition), triple reuptake inhibitors (combining norepinephrine and dopamine reuptake inhibition with SERT inhibition), and vortioxetine, a multimodal antidepressant combining actions at the G protein receptor mode (5HT1A and 5HT1B partial agonism and 5HT7 antagonism), at the ion channel mode (5HT3 antagonism) as well as the neurotransmitter transporter mode (SERT inhibition). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study of adults with MDD treated for 8 weeks with vortioxetine 2.5\u2009mg or 5\u2009mg per day, reductions in depression symptoms were not statistically significant compared with placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23252878",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, on the basis of these findings, vortioxetine (2.5, 5, 10\u2009mg/day) demonstrated a favourable safety and tolerability profile and maintained effectiveness over 12 months of treatment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22978748",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study of adults with MDD, 5 mg vortioxetine did not differ significantly from placebo in reducing depression symptoms after 6 wk of treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963932",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After 8 weeks of treatment with Lu AA21004 10 mg, there was a significant reduction in HDRS-24 total score compared with placebo in adults with MDD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22901346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, Lu AA21004 was efficacious and well tolerated in the treatment of elderly patients with recurrent major depressive disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22572889",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thus, Lu AA21004 was effective in preventing relapse of MDD and was well tolerated as maintenance treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495621",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Findings on secondary outcome measures, using MMRM instead of LOCF, were supportive of likely efficacy for Lu AA21004 5mg and 10mg and duloxetine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22209361",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, treatment with 5 mg and 10 mg Lu AA21004 for 6 wk was efficacious and well tolerated in patients with MDD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21767441",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results from phase II clinical trials have reported improvement in depression and anxiety symptoms after 6 weeks of treatment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21154150",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003866",
    "http://www.disease-ontology.org/api/metadata/DOID:1595",
    "http://www.disease-ontology.org/api/metadata/DOID:1596",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003865",
    "http://www.disease-ontology.org/api/metadata/DOID:1470",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016896"
  ],
  "exact_answer": "Yes"
}